BioCentury | Apr 13, 2018
Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
BioCentury | Nov 24, 2014
Product Development

LDL Does IMPROVE IT

The long-awaited results from the IMPROVE-IT cardiovascular outcomes trial have been hailed as opening the gates for next-generation cholesterol drugs to gain approval on the basis of LDL reductions alone. That may be true. But...
BioCentury | Nov 8, 2014
Top Story

FLINTy reception for Intercept

Although a Bloomberg report on The Lancet 's publication of data from the Phase II FLINT trial of obeticholic acid in non-alcoholic steatohepatitis (NASH) largely rehashed old ground, investors hammered shares of Intercept Pharmaceuticals Inc....
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; inflammation BET bromodomain proteins; bromodomain containing 4 (BRD4); NF-kB Mouse and cell culture studies suggest inhibitors against BET bromodomain proteins such as BRD4 could...
BioCentury | Jul 21, 2014
Politics, Policy & Law

Debating drug pricing

...improvements to health and quality of life delivered to patients. Medford is former CEO of AtheroGenics Inc....
BioCentury | Jan 20, 2014
Product Development

Next in NASH

Intercept Pharmaceuticals Inc. will need to resolve at least three things before its obeticholic acid can be approved and widely adopted for NASH. The company must settle on a Phase III trial design and address...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; hyperlipidemia Variability in response to cholesterol enriched atherogenic diet (DIET1); fibroblast growth factor 19 (FGF19) Mouse studies suggest inhibiting DIET1 could help treat atherosclerosis...
BioCentury | Jul 1, 2013
Product Development

POC for APOCIIIRx

If initial Phase II data bear out in larger trials, Isis Pharmaceuticals Inc. thinks ISIS-APOCIIIRx could alter the treatment landscape for hypertriglyceridemia much like statins did for hypercholesterolemia. ISIS-APOCIIIRx is an antisense inhibitor of apolipoprotein...
BioCentury | Dec 3, 2012
Emerging Company Profile

Lipigon: LPL protectorate

Lipoprotein lipase has long been a desirable target to treat atherosclerosis, but direct-acting activators of the enzyme have failed. Lipigon Pharmaceuticals AB is taking a different tack, developing small molecules that protect the enzyme from...
BioCentury | Nov 12, 2012
Clinical News

Epanova: Phase III data

Additional data from the double-blind, international Phase III EVOLVE trial in 399 patients with triglyceride levels of 500-2,000 mg/dL showed that once-daily 2 and 4 g Epanova non-significantly increased mean HDL-C from baseline to week...
Items per page:
1 - 10 of 261
BioCentury | Apr 13, 2018
Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
BioCentury | Nov 24, 2014
Product Development

LDL Does IMPROVE IT

The long-awaited results from the IMPROVE-IT cardiovascular outcomes trial have been hailed as opening the gates for next-generation cholesterol drugs to gain approval on the basis of LDL reductions alone. That may be true. But...
BioCentury | Nov 8, 2014
Top Story

FLINTy reception for Intercept

Although a Bloomberg report on The Lancet 's publication of data from the Phase II FLINT trial of obeticholic acid in non-alcoholic steatohepatitis (NASH) largely rehashed old ground, investors hammered shares of Intercept Pharmaceuticals Inc....
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; inflammation BET bromodomain proteins; bromodomain containing 4 (BRD4); NF-kB Mouse and cell culture studies suggest inhibitors against BET bromodomain proteins such as BRD4 could...
BioCentury | Jul 21, 2014
Politics, Policy & Law

Debating drug pricing

...improvements to health and quality of life delivered to patients. Medford is former CEO of AtheroGenics Inc....
BioCentury | Jan 20, 2014
Product Development

Next in NASH

Intercept Pharmaceuticals Inc. will need to resolve at least three things before its obeticholic acid can be approved and widely adopted for NASH. The company must settle on a Phase III trial design and address...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; hyperlipidemia Variability in response to cholesterol enriched atherogenic diet (DIET1); fibroblast growth factor 19 (FGF19) Mouse studies suggest inhibiting DIET1 could help treat atherosclerosis...
BioCentury | Jul 1, 2013
Product Development

POC for APOCIIIRx

If initial Phase II data bear out in larger trials, Isis Pharmaceuticals Inc. thinks ISIS-APOCIIIRx could alter the treatment landscape for hypertriglyceridemia much like statins did for hypercholesterolemia. ISIS-APOCIIIRx is an antisense inhibitor of apolipoprotein...
BioCentury | Dec 3, 2012
Emerging Company Profile

Lipigon: LPL protectorate

Lipoprotein lipase has long been a desirable target to treat atherosclerosis, but direct-acting activators of the enzyme have failed. Lipigon Pharmaceuticals AB is taking a different tack, developing small molecules that protect the enzyme from...
BioCentury | Nov 12, 2012
Clinical News

Epanova: Phase III data

Additional data from the double-blind, international Phase III EVOLVE trial in 399 patients with triglyceride levels of 500-2,000 mg/dL showed that once-daily 2 and 4 g Epanova non-significantly increased mean HDL-C from baseline to week...
Items per page:
1 - 10 of 261